Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...

The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

The exosome therapies market is expected to experience significant growth due to increased interest in regenerative medicine, cancer treatments, and drug delivery systems. Leading Indications ...

Capricor Therapeutics has completed its submission of a biologics license application (BLA) seeking U.S. approval of deramiocel, the company’s cell therapy for heart muscle disease in people with ...

Linda Marbán, CEO of cell and exosome-based therapy biotech Capricor Therapeutics, agreed that the industry will be watching closely. And despite the swirling gloom, some of last year’s “cautious ...

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that ...

On Friday, H.C. Wainwright reaffirmed a Buy rating with a price target of $77.00 on Capricor Therapeutics (NASDAQ:CAPR) shares. The firm's analyst highlighted the completion of a rolling Biologics ...